Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers

by Wietske I. Luining, Dennie Meijer, Max R. Dahele, André N. Vis, Daniela E. Oprea-Lager
Published 2021-01-01

Quantitative implications of the updated EARL 2019 PET–CT performance standards

by Andres Kaalep, Coreline N. Burggraaff, Simone Pieplenbosch, Eline E. Verwer, Terez Sera, Josee Zijlstra, Otto S. Hoekstra, Daniela E. Oprea-Lager, Ronald Boellaard
Published 2019-12-01

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

by Frank J. Borm, Jasper Smit, Daniela E. Oprea-Lager, Maurits Wondergem, John B. A. G. Haanen, Egbert F. Smit, Adrianus J. de Langen
Published 2021-06-01

Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer.

by Daniela E Oprea-Lager, Andrew D Vincent, Reindert J A van Moorselaar, Winald R Gerritsen, Alfons J M van den Eertwegh, Jonas Eriksson, Ronald Boellaard, Otto S Hoekstra
Published 2012-01-01

M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting

by Shafak Aluwini, Daniela E. Oprea‐Lager, Hilda deBarros, Niven Mehra, Herman Stoevelaar, Derya Yakar, Henk van derPoel, Dutch M1a Prostate Cancer Working Group
Published 2021-05-01

Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer

by Matthijs C. F. Cysouw, Gerbrand M. Kramer, Dennis Heijtel, Robert C. Schuit, Michael J. Morris, Alfons J. M. van den Eertwegh, Jens Voortman, Otto S. Hoekstra, Daniela E. Oprea-Lager, Ronald Boellaard
Published 2019-07-01

External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage...

by Henk B. Luiting, Sebastiaan Remmers, Dennie Meijer, André N. Vis, Maarten Donswijk, Daniela E. Oprea-Lager, Louise Emmett, Isabel Rauscher, Henk G. Van der Poel, Monique J. Roobol, Pim J. van Leeuwen
Published 2021-06-01

Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.

by Dennie Meijer, Bernard H E Jansen, Maurits Wondergem, Yves J L Bodar, Sandra Srbljin, Annelies E Vellekoop, Bram Keizer, Friso M van der Zant, Otto S Hoekstra, Jakko A Nieuwenhuijzen, Max Dahele, André N Vis, Daniela E Oprea-Lager
Published 2020-01-01

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial

by Chris Dickhoff, Suresh Senan, Famke L. Schneiders, Joris Veltman, Sayed Hashemi, Johannes M. A. Daniels, Marieke Fransen, David J. Heineman, Teodora Radonic, Peter M. van de Ven, Imke H. Bartelink, Lilian J. Meijboom, Juan J. Garcia-Vallejo, Daniela E. Oprea-Lager, Tanja D. de Gruijl, Idris Bahce
Published 2020-08-01

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

by Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Published 2020-09-01

Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Duc...

by Bart Geboers, Florentine E. F. Timmer, Alette H. Ruarus, Johanna E. E. Pouw, Evelien A. C. Schouten, Joyce Bakker, Robbert S. Puijk, Sanne Nieuwenhuizen, Madelon Dijkstra, M. Petrousjka van den Tol, Jan J. J. de Vries, Daniela E. Oprea-Lager, C. Willemien Menke-van der Houven van Oordt, Hans J. van der Vliet, Johanna W. Wilmink, Hester J. Scheffer, Tanja D. de Gruijl, Martijn R. Meijerink, on behalf of the Dutch Pancreatic Cancer Group
Published 2021-08-01